Trials / Completed
CompletedNCT01248897
Study of Biomarker Profiles in Asia Pacific erb2+/HER2 Breast Cancer Patients Treated With Lapatinib
A Study of Biomarker Profiles in Asia Pacific erbB2+/HER2 Breast Cancer Patients Treated With Lapatinib and Other Anti-erbB2/HER2 Therapy
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 158 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- Female
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to understand how information of 3 specific biomarkers can provide guidance to physicians in the treatment of erbB2 positive breast cancer patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | This study is non-interventional study, so this section is not applicable. | This study is non-interventional study, so this section is not applicable. |
Timeline
- Start date
- 2010-08-17
- Primary completion
- 2013-12-01
- Completion
- 2014-09-05
- First posted
- 2010-11-25
- Last updated
- 2018-06-19
Locations
17 sites across 4 countries: Hong Kong, Philippines, Singapore, South Korea
Source: ClinicalTrials.gov record NCT01248897. Inclusion in this directory is not an endorsement.